Posts by tag
cardiotoxicity
Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib plus the BCL2 inhibitor venetoclax (with or without the CD20 inhibitor obinutuzumab), delivered as fixed-duration therapies, significantly improved progression free survival in comparison with standard-of-care chemotherapy in previously untreated patients…
Common blood pressure drug could be used in AML to cut cardiotoxicity and improve response to chemotherapy
Treating acute myeloid leukaemia with losartan, a commonly used blood pressure agent, achieved the dual benefits of enhancing chemotherapy efficacy and preventing cardiotoxicity in a mouse model. The study, published in Science Translational Medicine, 19 June, demonstrated both benefits were…
New options to protect long-term health of children treated for cancer
Childhood cancer is considered a success story of modern medicine, with more than 90% of children now surviving long-term in high-income countries, up from just 10% 65 years ago. Yet many children who survive their cancer go on to experience…
ACE inhibitor protects against cardiotoxicity
In HER2 breast cancer, concurrent use of the ACE inhibitor lisinopril with trastuzumab-anthracyclines benefits left ventricular ejection fraction (LVEF). The study, abstract 509, presented in a poster session at the ASCO meeting, June 4-8, found breast cancer patients treated with…